UBS analyst Kevin Caliendo raised the firm’s price target on Premier (PINC) to $28.25 from $26 and keeps a Neutral rating on the shares after the company entered into an agreement to be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PINC:
- Hold Rating Maintained Amid Premier’s Acquisition by Patient Square Capital
- Premier price target raised to $28.25 from $25 at Canaccord
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- Premier Announces Merger with Patient Square Capital
- Premier to be acquired by Patient Square Capital for $28.25 per share in cash